FDA FAST TRACK DESIGNATION FOR NARMAFOTINIB IN ADVANCED PANCREATIC CANCER
Amplia Therapeutics Limited (ASX: ATX), ("Amplia" or the "Company"), is pleased to announce that the United States Food and Drug Administration (FDA) has granted Fast Track Designation to Amplia's Focal Adhesion Kinase inhibitor, narmafotinib, for the treatment of advanced pancreatic cancer.